NAFDAC's 5+5 Policy Boosts Nigeria's Pharmaceutical Sector

The National Agency for Food and Drug Administration and Control (NAFDAC) has reported that its 5+5 policy, introduced in 2018, is yielding significant results in Nigeria's pharmaceutical sector. Director General Prof. Mojisola Christianah Adeyeye highlighted the positive impact of this strategy during a courtesy visit from the Indonesian Ambassador to Nigeria, Bambang Suharto.
The policy aims to promote local pharmaceutical production and has successfully attracted foreign investors to establish manufacturing plants in Nigeria. Prof. Adeyeye noted that Nigeria is set to attain World Health Organization maturity level 3 with a recertification expected in 2025, which positions the country as a favorable destination for pharmaceutical investments.
NAFDAC operates a state-of-the-art biological vaccine laboratory in Yaba, Lagos, enhancing Nigeria's regulatory capabilities within Sub-Saharan Africa. Prof. Adeyeye reaffirmed NAFDAC's commitment to the 5+5 policy and expressed readiness to support prospective investors looking to establish manufacturing facilities in Nigeria.
Plus234Feed summary based on reporting from Blueprint. Read the original report below.
Read full article
Continue on Blueprint
Get the week in one email
Top stories, NPFL results, the naira — every Friday morning. Free, one email a week.
Related Stories

NAFDAC Destroys ₦1 Trillion in Counterfeit Drugs

FG Reaffirms Commitment to Local Pharmaceutical Manufacturing

Nigeria Enhances Monitoring to Block Fake Drugs in Trade Zones

NAFDAC Calls for Investment in Women and Children

NAFDAC, NOA, FCCPC Launch Campaign Against Sachet Alcohol

Nigeria Allocates 5% GDP to Industrial Financing Policy
Get Plus234Feed on messaging apps
Same headlines, delivered where you already scroll.






